CelLBxHealth plc (AIM:CLBX)

Market Cap	10.80M -63.6%
Revenue (ttm)	2.62M +29.6%
Net Income	-15.78M
EPS	-0.05
Shares Out	1.14B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	280,767
Average Volume	1,212,752
Open	0.9700
Previous Close	0.9500
Day's Range	0.9000 - 1.0000
52-Week Range	0.8500 - 11.8450
Beta	0.19
RSI	39.02
Earnings Date	Jun 1, 2026

About CelLBxHealth

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytic...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 119
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CLBX

Financial Performance

In 2024, CelLBxHealth's revenue was 2.86 million, an increase of 30.92% compared to the previous year's 2.19 million. Losses were -14.23 million, -29.34% less than in 2023.